【礼来计划投资至少270亿美元 在美国新建四个药物生产基地】当地时间周三,美国制药巨头礼来公司宣布,将投资至少270亿美元在美国新建四个生产基地。目前市场对礼来减肥药和糖尿病药物的需求还在不断上升,此外,该公司也在为其他疾病开发新药,寻求多元化其产品线,以巩固其在制药行业的地位。 据悉,在计划投资的四个生产基地,其中三个将专注于生产活性药物成分以及进一步强化供应链,例如减肥药Zepbound和糖尿病治疗药物Mounjaro的活性成分替尔泊肽,第四个生产基地则聚焦未来注射疗法。

金融界
27 Feb
当地时间周三,美国制药巨头礼来公司宣布,将投资至少270亿美元在美国新建四个生产基地。目前市场对礼来减肥药和糖尿病药物的需求还在不断上升,此外,该公司也在为其他疾病开发新药,寻求多元化其产品线,以巩固其在制药行业的地位。 据悉,在计划投资的四个生产基地,其中三个将专注于生产活性药物成分以及进一步强化供应链,例如减肥药Zepbound和糖尿病治疗药物Mounjaro的活性成分替尔泊肽,第四个生产基地则聚焦未来注射疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10